Polen Focus Growth Strategy cuts Eli Lilly position, but keeps faith in the drugmaker’s outlook

Polen Capital’s “Polen Focus Growth Strategy” took a smaller position in Eli Lilly and Company, according to the firm’s Q3 2026 investor letter circulated to clients this week. The change, reported by Yahoo Finance, reflects a portfolio adjustment rather than a shift in the fund’s fundamental view of the drugmaker.

The letter comes as investors continue to weigh how large-cap healthcare companies manage growth, pipeline progress, and pricing dynamics. Polen did not present a detailed public rationale for the cut in the portion of the communication described in the market coverage, but it characterized the move as consistent with staying confident in its outlook for Lilly.

Alongside the Lilly trim, the investor letter commentary noted that the Polen Focus Growth Strategy outperformed the Russell 1000 Growth Index. The comparison suggests the fund’s broader stock-selection approach was a headwind for the benchmark during the period, even as it trimmed at least one high-profile holding.

Polen’s portfolio action adds to a pattern investors have seen across growth-focused strategies during 2026: actively managing positions even when investors remain constructive. In practical terms, trimming a stake can be driven by valuation, risk management, or internal reassessment of a company’s nearer-term path, without implying a downturn in longer-term expectations.

For Eli Lilly, which is closely watched by both clinicians and markets because of its role in major therapeutic areas, changes in institutional ownership can be meaningful indicates for liquidity and sentiment. However, a single investor letter does not constitute an earnings forecast or a change in company guidance. The market write-up indicates Polen reduced exposure while continuing to express confidence, which can limit how much the news should be read as a negative development for Lilly’s fundamentals.

Sector context matters here. Healthcare tends to draw steady long-term capital, but growth-oriented holders often respond to shifting expectations around demand, manufacturing capacity, competitive dynamics, and regulatory timelines. Without additional disclosure from Polen about the magnitude of the trim or the specific drivers, it is difficult to attribute the move to any one factor affecting Lilly.

The available coverage does not disclose how much Polen trimmed the Eli Lilly position, whether the firm sold shares outright or reduced through incremental trades, or what internal metrics drove the decision. It also does not specify whether the firm changed its views on particular pipeline assets, commercial performance, or risk factors tied to Lilly’s future growth.